



ASX release

10 March 2015

American Medical Association (AMA) accepts recommendation for Category 1 CPT Code for arterial pressure waveform assessment

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor[®] system which measures central aortic blood pressures and arterial stiffness non-invasively, today announced that the American Medical Association (AMA) has posted its CPT Editorial summary of panel actions from the February 6-8, 2015 CPT Panel meeting. The CPT panel made a recommendation to accept the Renal Physician Associations (RPA) application for addition of Category 1 CPT code 9300X1 and to delete Category III code 0311T for non-invasive calculation and analysis of central arterial pressure waveforms with interpretation and report. Category I CPT codes are reserved for those procedures that have demonstrated clinical efficacy, are performed by many physicians or other qualified health care professionals across the United States and have US Food and Drug Administration (FDA) clearance.

"This is a seminal event in AtCor Medical's history. Building a clinical business in the world's largest medical device market has been a cornerstone of AtCor Medical's investment strategy since our IPO in 2005. This addition marks a significant step toward more widespread clinical adoption and greater patient access to life-saving technology", said Duncan Ross, CEO and president of AtCor Medical. "AtCor has built a highly skilled US team with a solid customer base that includes all 17 hospitals on the US News and World Report best hospitals Honor Roll. Our company has relationships of trust with key opinion leaders (KOLs) in both research and clinical practice. Our relationships with key medical societies are well established. AtCor is well positioned to capitalise on increasing customer demand and market access."

Current Procedural Terminology (CPT), maintained by the CPT Editorial Panel which meets three times a year, is a listing of descriptive terms and identifying codes for reporting medical services and procedures. The purpose of CPT is to provide a standardised language that accurately describes medical, surgical and diagnostic services, and thereby serves as an effective means for consistent nationwide communication among physicians and other healthcare providers, patients, and third parties in the United States. CPT is the most widely accepted medical nomenclature used to report medical procedures and services under public and private health programs.

Note that this is a result of the most recent CPT Editorial Panel meeting. Future CPT Editorial Panel actions may impact this information. New and revised code descriptions may be further refined prior to publication each year. For this reason, code numbers are neither assigned, nor exact wording finalised, until just prior to publication of the annual CPT code set. Decisions made from this panel meeting become effective 1 January 2016, following successful completion of the process noted below.

The yearly release of the updated CPT codes set is timed to coincide with the annual Medicare Physician Fee Schedule (MPFS). Following the February creation of a new CPT Category I code for central arterial pressure waveforms assessment, the code is surveyed as part of the AMA/Specialty Society RVS Update Committee's (RUC) review. The RUC makes recommendations to the Centers for Medicare and Medicaid Services (CMS) on physician work, practice expense inputs and professional liability insurance crosswalks. These are all elements in the MPFS which contribute to the Medicare fee for the service as well as the basis for commercial insurance contracted rates. The RUC will develop recommendations on the code for arterial pressure waveform assessment in April of 2015. The final fees will be published by CMS in early November 2015.

AtCor Medical will host an investor conference call on 11 March (tomorrow) at 9:00am AEDT to discuss this decision. Conference call details will be provided in an announcement later today.

About AtCor Medical

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to measure central aortic blood pressure non-invasively. The company's SphygmoCor® system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 3,700 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 800 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

*For further information, please contact
(AtCor):*

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations

Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au